Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
118 hedge funds and large institutions have $439M invested in Keryx Biopharmaceuticals Inc in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 47 reducing their positions, and 26 closing their positions.
41% more capital invested
Capital invested by funds: $312M → $439M (+$128M)
16% more call options, than puts
Call options by funds: $5.35M | Put options by funds: $4.62M
9% less funds holding
Funds holding: 130 → 118 (-12)
45% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 47
46% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.5M |
| 2 |
Millennium Management
New York
|
+$3.7M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.15M |
| 4 |
Goldman Sachs
New York
|
+$2.02M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$745K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$3.34M |
| 2 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$2.79M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.24M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$1.85M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.79M |
KERX Hedge Fund Activity: Q2 2016 in Review
118 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q2 2016, worth a combined $439M — up 41% from $312M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of KERX and 14 opened new positions — a net loss of 12 holders — while 47 trimmed existing stakes and 26 added.
The largest buyer was Fidelity Investments, adding an estimated $5.5M. The largest seller was BlackRock Fund Advisors, cutting an estimated $3.34M.
- 118 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q2 2016, down from 130 in Q1 2016.
- Funds reported $439M of Keryx Biopharmaceuticals Inc stock for Q2 2016, up 41% quarter-over-quarter.
- 14 funds opened new Keryx Biopharmaceuticals Inc positions in Q2 2016 and 26 closed out, a net change of -12 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q2 2016 was Fidelity Investments, an estimated $5.5M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q2 2016 was BlackRock Fund Advisors, an estimated $3.34M sold.
Based on aggregated 13F filings for Q2 2016.